

Eligibility Criteria

Patients must:

1. Be 40 to 79 years age, with a definitive histological diagnosis of PCa by needle biopsy.
2. Have high risk PCa where at least one of the following three factors is satisfied:
 - 1) initial PSA > 20 ng/mL, 2) Clinical stage of T2c or T3a, 3) Gleason score 8-10.
3. Be previously untreated for prostate cancer.
4. Demonstrate appropriate bone marrow, hepatic and renal function in laboratory tests within two weeks prior to registration.
 - a) WBC $\geq 3,000 /\mu\text{L}$
 - b) Hemoglobin level $\geq 10.0 \text{ g/dL}$
 - c) Platelet count $\geq 10.0 \times 10^4 /\mu\text{L}$
 - d) Serum creatine level $\leq 2.0 \text{ mg/dL}$
 - e) ALT and AST levels $\leq 100 \text{ IU/L}$
5. Agree in writing to participate in this clinical study after receiving adequate explanation.

